James Weissman Net Worth, Biography, and Insider Trading
James B.  Weissman net worth and biography

James Weissman Biography and Net Worth

James B. Weissman serves as Chief Operating Officer, Executive Vice President of the Company. He has more than 30 years’ experience in the life sciences industry, with extensive international management experience in biotech and pharmaceutical general management, product development, licensing, business development, marketing, and merger and acquisition activities. Mr. Weissman serves on the board of Receptor Holdings, Inc. Prior to Dicerna, Mr. Weissman was Vice President of Business Development at MannKind Corporation, responsible for leading the company’s activities relating to licensing, new products, and strategic planning. Prior to MannKind, Mr. Weissman held leadership positions in both business development and marketing at Pfizer Pharmaceuticals, Inc. in Tokyo, most recently as Senior Director of Marketing. In that position, he was responsible for the sales, profit, and strategic targets for the company’s specialty products, including central nervous system (CNS) endocrinology, ophthalmology and oncology therapeutics, and diversified portfolios. Mr. Weissman holds a Bachelor of Science degree from Bates College.

What is James B. Weissman's net worth?

The estimated net worth of James B. Weissman is at least $0.00 as of April 16th, 2021. Mr. Weissman owns 16,000 shares of Dicerna Pharmaceuticals stock worth more than $0 as of April 5th. This net worth estimate does not reflect any other investments that Mr. Weissman may own. Learn More about James B. Weissman's net worth.

How do I contact James B. Weissman?

The corporate mailing address for Mr. Weissman and other Dicerna Pharmaceuticals executives is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. Dicerna Pharmaceuticals can also be reached via phone at (617) 621-8097 and via email at cerdman@macbiocom.com. Learn More on James B. Weissman's contact information.

Has James B. Weissman been buying or selling shares of Dicerna Pharmaceuticals?

James B. Weissman has not been actively trading shares of Dicerna Pharmaceuticals within the last three months. Most recently, James B. Weissman sold 30,000 shares of the business's stock in a transaction on Tuesday, July 6th. The shares were sold at an average price of $39.09, for a transaction totalling $1,172,700.00. Learn More on James B. Weissman's trading history.

Who are Dicerna Pharmaceuticals' active insiders?

Dicerna Pharmaceuticals' insider roster includes Shreeram Aradhye (EVP), Bob Brown (EVP), Robert Ciappenelli (Insider), Douglas Fambrough (CEO), Marc Kozin (Director), Regina Paglia (Insider), James Weissman (COO), and Ling Zeng (Insider). Learn More on Dicerna Pharmaceuticals' active insiders.

James B. Weissman Insider Trading History at Dicerna Pharmaceuticals

James B. Weissman Buying and Selling Activity at Dicerna Pharmaceuticals

This chart shows James B Weissman's buying and selling at Dicerna Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2$0Total Insider BuyingTotal Insider Selling

Dicerna Pharmaceuticals Company Overview

Dicerna Pharmaceuticals logo
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $38.12
Low: $37.81
High: $38.25

2 Week Range

Now: N/A

Volume

N/A

Average Volume

1,344,033 shs

Market Capitalization

$2.99 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8